ORTHOPEDIATRICS CORP (KIDS) Form 10-Q — Oct 28, 2026
OrthoPediatrics reported Q3 2026 net revenue of $72.7 million, up 19% year-over-year, driven by strong Trauma and Deformity (+19%) and Scoliosis (+18%) sales. Nine-month revenue reached $202.5 million, up 16%. Net loss narrowed to $5.9 million ($0.25/share) from $11.8 million ($0.50/share) a year ago, and the company generated $2.1 million of positive operating cash flow versus a $15.2 million cash burn in the prior-year period. The company holds $44.9 million in cash and short-term investments against $104.6 million in total debt, and secured a new $20 million undrawn delayed-draw facility from Braidwell in March 2026.
Key figures
- Revenue
- 72661000
- Total Debt
- 104605000
- Revenue Yoy
- 19% (Q3); 16% nine-month
- Total Assets
- 509087000
- Cash Position
- 44900000
- Shares Outstanding
- 26110476
- Gross margin
- 74%
- Q3 2025 revenue
- 61250000
- Nine month revenue
- 202530000
- Accumulated deficit
- 298992000
- Operating cash flow 9m
- 2147000
- Unrecognized stock comp
- 21498000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.